Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report
Authors:
- 18 October 2016
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 165 (8) , 607-608
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ TumorsCancer Research, 2015
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaNew England Journal of Medicine, 2015
- Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosisLeukemia, 2012
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)Proceedings of the National Academy of Sciences, 2008
- Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive anaplastic large-cell lymphomaBlood, 2007